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if it is in the right direction.
—Winston Churchill (1)
In 1959, Thomas Dawber published the first in a series of
landmark papers from the Framingham cohort, identifying
what he coined “risk factors” for the development of heart
disease; these included hypertension, high total cholesterol,
and smoking (2). For almost 30 years following this seminal
observation, total cholesterol had been used as a primary
measure of risk, when in 1988, the National Cholesterol
Education Program’s Adult Treatment Panel (ATP) sug-
gested using low-density lipoprotein cholesterol (LDL-C)
as the principal marker for initiating and targeting treat-
ment (3). Since then, numerous studies have confirmed the
importance of LDL-C in risk assessment and intervention,
with statins have risen to become the most prescribed
therapeutic class of agents in the United States (4,5).
Although LDL-C reduction with statins have dramatically
advanced our treatment of coronary heart disease (CHD), a
substantial residual risk of CHD events remains in statin-
treated patients, even in patients achieving an LDL-C 70
mg/dl, thus challenging the predictive power of LDL-C
level for CHD and highlighting the need to focus on other
lipid markers in risk assessment and intervention (6,7). In
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the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction 22) trial (8), a statin trial focusing
on comparative LDL cholesterol treatment objectives
post-myocardial infarction, a lower on-treatment triglyc-
eride level of 150 mg/dl was independently associated
with reduced CHD risk compared with higher triglycer-
ide levels, suggesting that non– high-density lipoprotein
cholesterol (HDL-C) (the sum of LDL-C and very
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vide a superior therapeutic target for risk intervention
than LDL-C alone.
The evidence highlighting excess residual risk, however,
is never more explicit than in patients with diabetes and/or
metabolic syndrome, where lipid profiles are generally char-
acterized by relatively low levels of LDL- and HDL-C, but
elevated levels of triglycerides and small dense LDL parti-
cles (9,10). In a meta-analysis of over 90,000 CHD patients
enrolled in 14 statin trials, the residual risk for major
vascular events observed in statin-treated diabetics exceeded
that of nondiabetic CHD patients treated with placebo,
dramatizing the inadequacy of exclusively targeting LDL-C
in diabetics (11). This fact is particularly relevant, given the
explosive increase in the prevalence of obesity and subse-
quent metabolic syndrome and diabetes that result from it;
today, nearly 70% of U.S. adults are classified as overweight
or obese compared with fewer than 25% 40 years ago
(12–14). Over that same time frame, the prevalence of
diabetes as a percentage of the U.S. population quadrupled,
now present in 8.3% of the U.S. population and continuing
to rise (15,16).
In recognition of these trends, the ATP III suggested
non–HDL-C as a “secondary endpoint,” targeting a goal for
therapy 30 mg/dl higher than the recommended LDL-C
goal, but only in patients with triglyceride levels between
200 to 499 mg/dl and after achieving target LDL-C goals
(17). Because non–HDL-C was relegated to a secondary
endpoint, and its use as a secondary target was recom-
mended only under specific circumstances, few clinicians
became aware of it, and fewer diabetic patients achieved this
recommended endpoint (18–20). The resulting treatment
gap led to the more recent publication of a joint consensus
report from the American Diabetes Association and the
American College of Cardiology promoting the concept of
global cardiometabolic risk assessment that recognizes many
of the manifestations of obesity and metabolic syndrome,
including insulin resistance, inflammation, and elevation of
triglycerides and apolipoprotein (apo) B (21). The state-
ment further recommends lipid treatment goals for CHD
and/or diabetic patients, as well as high-risk patients with 2
or more major CHD risk factors, that extend well beyond
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July 26, 2011:464–6 Refining Risk StratificationLDL-C and include apoB and non–HDL-C as combined
primary targets of therapy (Table 1).
Many studies now document that apoB levels, which
represent the total number of atherogenic lipoprotein
particles, better correlates with CHD than does the
LDL-C level, both in untreated as well as statin-treated
patients (7,22–25). Similarly, non–HDL-C, which rep-
resents the cholesterol contained in all atherogenic apo-
B– containing lipoproteins, has also been demonstrated to
best LDL-cholesterol in predicting CHD (9,18,22,23,26).
In this issue of the Journal, Ramjee et al. (27) review the
data supporting the need to extend lipid risk assessment
and intervention beyond LDL-C, and compare the rela-
tive strengths and weakness of the 2 prime candidates to
replace LDL-C as the principal therapeutic lipid target,
namely apoB and non–HDL-C. Although both of these
parameters are relatively similar in out-performing
LDL-C in risk stratification, the authors point out the
practical advantages of using non–HDL-C, namely its
low cost (no additional cost), rapid turn-around time, and
easier conceptualization by the majority of practicing
clinicians, than the introduction of a “new” lipid param-
eter such as apoB. These practical advantages are not
trivial, and they argue strongly for its adoption to replace
LDL-C as the principal therapeutic target for lipid
intervention (28). Moreover, a recent guideline statement
from the American College of Cardiology and the Amer-
ican Heart Association support these conclusions and
propose that apo-B, as well as particle size and density,
not be measured in cardiovascular risk assessment (Class
III, Level of Evidence: C) (29). Although these debates
among risk factors are worthwhile and necessary, we
should not, however, lose sight of our primary goal: the
further reduction and eventual elimination of residual
risk in CHD. Taken together, non–HDL-C offers an
attractive and inexpensive therapeutic target for risk
reduction in all patients at risk for CHD, and with the
continued cardiometabolic changes in the population, a
more relevant primary target of intervention in the
uggested Treatment Goals in Patientsith CMR and Lipoprotein AbnormalitiesTable 1 Suggested Treatment Goals in PatientsWith CMR and Lipoprotein Abnormalities
LDL-C
(mg/dl)
Non–HDL-C
(mg/dl)
ApoB
(mg/dl)
CHD patients or diabetic patients
with 1 or more additional major
CHD risk factor
70 100 80
1) High-risk patients without diabetes
or CHD but 2 or more major CHD
risk factors; or 2) diabetic patients
without other major CHD risk
factors
100 130 90
Other major risk factors include smoking, hypertension, and family history of premature CHD.
Adapted from Brunzell et al. (21).
apoB apolipoprotein B; CHD coronary heart disease; CMR cardiometabolic risk; HDL-C
igh-density lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol.modern era.Reprint requests and correspondence: Dr. Richard V. Milani,
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